SPDR® S&P Biotech ETF
Analysts’ Recommendations for United Therapeutics
In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.
How Stocks and Bonds Reacted to Trump’s Victory
The CBOE Volatility Index suddenly rose 6.0% on November 9, 2016, after it was clear that Trump had unexpectedly clinched the election.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Why Eylea Could Face Tough Competition in 2016
In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.
Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
How Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
What Are the Current Treatment Options for Hemophilia?
Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.
Biogen Stock Trending Higher on Strong Q2 2018 Results
Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.
Baxalta in the XBI Top Ten Large Caps
Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.
Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018
Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).
Incyte Was a Star Performer from August 10–17, 2015
By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.
Why you should use the Sharpe ratio when investing in the medical device industry
What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]
Why Portola Pharmaceuticals Rose 8.09% on January 4
On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Intellia Therapeutics Stock Fell 9.8% on Monday
On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.
Biotech Sector Continue to Dazzle Despite Market Distress
Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes.
Viking Therapeutics Stock Rose 101% on May 31
On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.
Why the Physician Office Pain Management Market Matters to MiMedx
Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.
Comparing Cara Therapeutics’ Financial Performance
Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]
A Strong Pipeline of Drugs Bodes Well for Radius Health
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.
Patisiran Expected to Become Key Growth Driver for Alnylam
Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.
Benefitting from IBB’s Lower Expense Ratio
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
What Analysts Recommend for Acadia Pharmaceuticals in September
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
Are Stock Returns during Summer Months That Bad?
The health care sector (IBB) (VHT) (XBI) has been the most challenged sector since Donald Trump’s presidential campaign.
The Larger Aims of Obamacare: An Overview
The idea behind Obamacare was that it would embody legislation not only providing but mandating healthcare coverage for nearly everyone in the US.
Is Rising Consumer Sentiment Helping the Market Rally in 2017?
The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.
What Do Analysts Recommend for Gilead Sciences Stock?
According to a Reuters consensus of 26 brokerage firms on November 22, 2016, 88% of the analysts recommended Gilead as a “buy.”
Which S&P 500 Sectors Do the Best for an Incumbent Democrat?
The S&P 500 returns for a second-term president have been somewhat better than a first-term president, which is one reason for the incumbency factor.
$1 Billion Sales Target in Place for Tyvaso
United Therapeutics’ Tyvaso’s strong profile and patent protection until the late 2020s is expected to enable it to reach annual sales of $1 billion.
How Significant Is Alexion’s Opportunity with Soliris?
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.
FOMC Keeps the Door Open for a Live Meeting in September
The Fed had a meeting on July 27 to decide on the monetary policy. The tone of the Fed’s statement made a case for the September meeting to be a live one.
The Novartis-Xencor Collaboration Agreement: The Details
Novartis, one of the largest pharmaceutical companies, announced a collaboration and licensing agreement with Xencor on June 28, 2016.
Understanding the Sales Potential of United Therapeutics’ Orenitram
United Therapeutics’ (UTHR) Orenitram is an oral medication containing the prostacyclin analogue, trepostinil.
How Are XBI’s Holdings’ Moving Averages Trending?
On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%
As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).
XBI Tops the Biotechnology ETFs in the Last Week of May
In the week ending May 27, 2016, the SPDR S&P Biotech ETF (XBI) was the top performer among biotechnology ETFs with a return of 5.1%.
Opportunities For Xtandi, Medivation’s Key Drug
Enzalutamide, known by its brand name Xtandi, is an androgen receptor inhibitor. It is the only commercialized product in Medivation’s (MDVN) portfolio.
SPDR Indexes across Energy and Gold Rise on Increase in Commodities
The SPDR S&P Metals & Mining ETF (XME) was the outperformer of the day on April 19.
Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue
Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.
Incyte Continues Its Growth Spree in 2015
Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.
Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?
If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.
DaVita’s Stock Reacts to the Merger with The Everett Clinic
DaVita HealthCare Partners (DVA) was one of the biggest winners for the week ending March 4 with a return of 6.1%.
Energy and Mining SPDRs Rally as Services Sector Declines
The metals and mining and oil production sectors took positive cues as commodity prices continued the rally on March 3, 2016. XOP was the outperformer among major sector-specific ETFs.
Revlimid Continues to Drive Celgene’s Revenue
Revlimid (lenalidomide) is one of Celgene’s (CELG) main revenue drivers. It had revenues of $1.4 billion in 3Q15, excluding the adverse impact of foreign exchange fluctuations.
Vimizim: A Recent Addition to BioMarin’s Portfolio
In 2014, Vimizim (elosulfase alfa) received marketing approval by the FDA, followed by the approval of the European Medicines Agency for treating MPS IV A.
Vertex Pharmaceuticals Brings up the Rear among XBI’s Large-Caps on December 3
Vertex Pharmaceuticals lost the most among the large-cap stocks on December 3, closing at $122.06—a decline of 6.4%.
The SPDR S&P Biotech ETF Lingers in the Red as of December 3
The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.
AbbVie Topped XBI’s Large-Cap Space
AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.
BioMarin Falls 16.81% in Week Ended September 25
BioMarin Pharmaceutical (BMRN) fell 16.81% and closed at $108.69 last week. That’s below the 20-day, 50-day, and 100-day moving averages. The 14-day RSI was 28, or oversold territory.
IBB Mid-Cap Outperforms XBI Mid-Cap
IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.
Top Ten of XBI Outperform by Market Cap
The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.
Alnylam and ISIS Lead Mid-Cap Stocks
Alnylam and ISIS led mid-cap stocks from August 25–31, 2015. Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% in IBB and 1.15% in XBI. The stock gained 10.89% in that period.
Top Ten XBI Stocks by Market Cap Outperform August 25–31
The top ten stocks of the SPDR S&P Biotech ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) and the Health Care Select Sector SPDR ETF (XLV) for August 25–31.
Comparing IBB’s and XBI’s Small-Cap Stocks
From August 10–17, 2015, the XBI top ten small-cap stocks outperformed the IBB’s top ten small-cap stocks. XBI small caps returned 1.04% while IBB small caps rose by 0.07% during the same period.
How Actavis Has Emerged through Mergers and Acquisitions
In October 2012, Actavis completed the acquisition of Actavis Group. In 2013, the company’s revenues outside the US increased to 29% from 16% in 2012.